Antimicrobial peptides (the alternate plural tag) covers the same field as #antimicrobial-peptide. Coverage runs across Peptilogics' biofilm work, Fedora's FPI-2119 lactivicin, Longhorn Vaccines' DRG5-BD11, and the HMD-AMP discovery platform from HLB Innovation.
The academic side has been productive. Groups at Birmingham (PEPITEM), Oxford, and others have published on AMP discovery, MRSA, and biofilm penetration. Nature Biomedical Engineering and Nature Biotechnology AMP papers continue to surface AI-discovered scaffolds.
For the singular form, see #antimicrobial-peptide. For the policy and resistance context, see #amr and #antibiotic-resistance.
A research team published in Frontiers in Pharmacology in June 2026 a machine-learning pipeline for discovering antimicrobial peptides active against Pseudomonas aeruginosa, one of the WHO's top-priority gram-negative pathogens for new antibiotic development. The model was externally validated using 124 experimentally confirmed AMPs from recent publications. Pseudomonas aeruginosa is a leading cause of ventilator-associated pneumonia and bloodstream infection in immunocompromised patients, and the rise of carbapenem-resistant strains has narrowed remaining treatment options to colistin and ceftolozane-tazobactam. The paper sits in a broader 2026 ML-AMP wave that also includes 'Advances in the Application of Deep Learning for Antimicrobial Peptide Screening' (Agricultural Science and Food Processing) and an arxiv preprint on multilabel AMP classification benchmarks. AMP discovery is one of the few peptide-drug verticals advancing in parallel to GLP-1 headlines, with no commercial obesity-driven distortion of academic publication pipelines.
A review published May 19 in Drug Delivery and Translational Research analyzed nano-antimicrobial peptides (nano-AMPs) — antimicrobial peptides packaged into nanoparticle delivery systems — as a strategy to overcome the three barriers that have kept AMPs out of the clinic despite decades of promise: systemic toxicity, proteolytic instability, and manufacturing cost. The review focuses on activity against multidrug-resistant Gram-negative bacteria, the hardest antimicrobial-resistance target where the conventional-antibiotic pipeline is thinnest. Nanoparticle encapsulation can shield AMPs from protease degradation, reduce off-target toxicity by controlling release, and improve tissue targeting. The piece joins the broader 2026 AMP research wave — AI-designed peptides (ProteoGPT, CAMPER), generative-AI discovery in Nature Microbiology, and ancient-microbiome AMP mining — that is collectively maturing the antimicrobial peptide field toward clinical viability against the ESKAPE pathogens responsible for most drug-resistant infections.
A Nature Microbiology paper (published May 22) reported a generative artificial-intelligence approach for discovering antimicrobial peptides against multidrug-resistant bacteria. The method uses transfer learning to give large language models domain-specific knowledge for high-throughput mining and generation of novel AMP candidates. The work joins the 2026 AI-AMP wave — ProteoGPT's 94.4% hit rate, the CAMPER mechanistic-AI MRSA platform, ancient-microbiome AMP mining, and the May 19 nano-AMP delivery review — that is collectively moving the antimicrobial peptide field from computational prediction toward clinical candidates. The convergence matters because antimicrobial resistance is projected to cause up to 10 million deaths annually by 2050, and the conventional small-molecule antibiotic pipeline has thinned to the point where membrane-targeting peptides with low resistance-development propensity are among the most credible near-term alternatives. The generative-AI design stack plus nanoparticle delivery addresses the two historical AMP bottlenecks — discovery throughput and the toxicity/stability/manufacturing gap — in parallel.
A 2026 Nature Communications paper introduced AMPLiT — a tool for screening antimicrobial peptide candidates in metagenomic datasets — and applied it to human coprolite metagenomes (ancient stool samples). The team identified candidate AMPs from extinct gut-microbiome lineages that have functional activity against modern multidrug-resistant pathogens. The approach extends the AMP-discovery search space from contemporary microbial sequences to the much-larger reservoir of evolutionary AMPs encoded in ancient host-microbiome assemblies preserved in archaeological samples. The strategy joins the broader 2026 AI-AMP wave (ProteoGPT, CAMPER, the AI-driven AMP characterization paper in Scientific Reports) as an alternative source of novel chemistry against ESKAPE pathogens. The work positions ancient-DNA-based AMP discovery as a credible track alongside computational design.
Fadi Shehadeh, Biswajit Mishra and collaborators published CAMPER (Constraint-driven AMP Engineering with Ranking) in Nature Communications 2026, integrating machine learning with mechanistic biological features to design peptides that target MRSA persister cells. The lead candidate, WP-CAMPER1, kills S. aureus MW2 at a minimal inhibitory concentration of 4 µg/mL. A 2% topical formulation reduced bacterial burden 2.5 log10 in a murine prophylactic skin infection model; the D-enantiomer WP-CAMPER1-d achieved 1.37 log10 reduction in established biofilm infections.
A Cell Biomaterials review published April 16 maps the AI-driven antibiotic-discovery landscape across two strategy families: mining (using discriminative models on genomic/proteomic sequence libraries) and generation (using diffusion and language models to design novel synthetic peptides exceeding nature's repertoire). Companion work flagged in the review includes the University of Pennsylvania AMP-Diffusion system, which produced tens of thousands of candidate peptides — 46 prioritized, three quarters bacterial-inhibitory, and two with in vivo efficacy matching approved antibiotics in mouse infection models.
A 2026 Discover Oncology review (Springer Nature) consolidated the case for antimicrobial peptides (AMPs) as anticancer therapeutics across three mechanistic categories: direct cytotoxicity through cancer-cell-membrane disruption (the same cationic-amphipathic chemistry that makes AMPs antibacterial works on the negatively charged outer leaflet of cancer-cell membranes), intracellular targeting of mitochondria and DNA replication, and use as vaccine adjuvants that boost immune responses to neoantigens. The review joins the May 2026 International Journal of Peptide Research piece on peptide cancer vaccines, the Frontiers in Medicine April 2026 anticancer AMP review, and the Frontiers in Bioinformatics March 2026 computational AMP discovery review as part of the AMP-as-cancer-therapeutic literature wave. Clinical translation remains limited: AMP-based cancer drugs in development are mostly preclinical or Phase 1.
April-May 2026 produced an unusual concentration of peer-reviewed advances against antimicrobial resistance, with peptide therapeutics anchoring much of the progress. The Frontiers in Bioinformatics March 17 review documented an AI/LLM pipeline (ProteoGPT) that produced 17 active peptides out of 18 designed (94.4% hit rate) in 48 days — collapsing the traditional discovery timeline. A Nature Microbiology generative-AI approach produced novel AMPs against multidrug-resistant bacteria with anti-inflammatory effects and minimal cytotoxic risk. Other April-May 2026 breakthroughs: Houston Methodist's CAMPER engineered against MRSA, the Manchester team's alternative ligase pathway to penicillins, and the Indian Institute of Technology Roorkee antibacterial peptide-drug conjugate against NDM-1/IMP-1 metallo-beta-lactamase pathogens. The combined wave signals the peptide-design stack has matured enough to compete directly with small-molecule antibiotic development.
A Frontiers in Bioinformatics review published March 17, 2026 from Tope Abraham Ibisanmi and colleagues at UNSW Sydney documents how computational antimicrobial peptide discovery has collapsed from decades to weeks. The review covers big-data mining, molecular dynamics simulations, and AI methods that capture complex sequence-activity relationships and predict novel AMPs from genomic and metagenomic data. The headline example: one large language model approach produced 18 de novo peptides of which 17 were active (94.4% hit rate) over a 48-day discovery cycle. The framing complements the broader AMP-as-AMR-response thesis with Aifeity, the University of Bonn, and Cesar de la Fuente at Penn — and lands as Cesar de la Fuente's Penn lab launches new generative AMR molecules into ESKAPE-pathogen testing.
A Frontiers in Medicine review published in 2026 consolidates the case for antimicrobial peptides (AMPs) as anticancer therapeutics and vaccine adjuvants. The cationic, amphipathic architecture that makes AMPs effective against bacterial membranes also enables selective electrostatic interactions with negatively charged malignant cell membranes — driving rapid membrane disruption and cell lysis. Beyond direct membrane effects, the review documents AMP-induced inhibition of DNA replication and protein synthesis, mitochondrial dysfunction, and tumor angiogenesis suppression. The piece also catalogs AMPs with adjuvant properties that boost vaccine immune responses against cancer and infectious disease. The work joins the Houston Methodist CAMPER MRSA paper, the Nature Communications few-shot Acinetobacter pipeline, and the Manchester penicillin-biosynthesis paper as part of the AMP wave through April–May 2026.
A Nature Communications paper describes a deep-learning pipeline that uses pre-trained protein language models combined with few-shot fine-tuning to identify antimicrobial peptides effective against Acinetobacter baumannii, a WHO critical-priority pathogen. The classification, ranking, and regression modules collaboratively prioritize candidates with high predicted activity, expanding the chemical space accessible to data-poor AMR targets. Lead candidates showed potent in vitro activity against carbapenem-resistant clinical isolates.
University of Nebraska Medical Center's Guangshun Wang lab released APD6, the expanded antimicrobial peptide database, containing 6,309 peptides (3,379 natural AMPs, 2,290 synthetic, 373 AI-predicted) as of January 2026. New features include the Antimicrobial Peptide Information Pipeline (AMPIP) and expanded functional wheel covering anticancer and antidiabetic activity — positioning APD6 as the most comprehensive reference for AMP drug discovery as AI-assisted antibiotic design accelerates.
A study published in Nature Microbiology used a generative AI approach to discover antimicrobial peptides effective against multidrug-resistant bacteria. The deep learning pipeline screened millions of candidate sequences, achieving a 94.4% success rate in lab validation, with two candidates showing exceptional efficacy and low resistance potential.